1. Home
  2. CNXN vs SNDX Comparison

CNXN vs SNDX Comparison

Compare CNXN & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CNXN

PC Connection Inc.

HOLD

Current Price

$64.24

Market Cap

1.5B

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$24.42

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNXN
SNDX
Founded
1982
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
2.2B
IPO Year
1997
2014

Fundamental Metrics

Financial Performance
Metric
CNXN
SNDX
Price
$64.24
$24.42
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
$38.69
AVG Volume (30 Days)
51.6K
1.4M
Earning Date
04-29-2026
05-04-2026
Dividend Yield
1.24%
N/A
EPS Growth
N/A
11.56
EPS
3.27
N/A
Revenue
N/A
$172,352,000.00
Revenue This Year
$6.24
$106.95
Revenue Next Year
$4.39
$40.94
P/E Ratio
$19.70
N/A
Revenue Growth
N/A
627.84
52 Week Low
$54.97
$8.59
52 Week High
$71.17
$25.59

Technical Indicators

Market Signals
Indicator
CNXN
SNDX
Relative Strength Index (RSI) 68.42 56.26
Support Level $61.71 $19.46
Resistance Level $65.39 $25.43
Average True Range (ATR) 1.64 1.22
MACD 0.72 -0.06
Stochastic Oscillator 93.14 64.73

Price Performance

Historical Comparison
CNXN
SNDX

About CNXN PC Connection Inc.

PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: